Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2013

01.10.2013 | Breast Oncology

Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Early-Stage Breast Cancer Patients Undergoing Breast Conservation, 2003–2010: A Report from the National Cancer Data Base

verfasst von: Tomasz Czechura, MPH, David J. Winchester, MD, Catherine Pesce, MD, Dezheng Huo, MD, PhD, David P. Winchester, MD, Katharine Yao, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous studies have demonstrated an increase in the utilization of accelerated partial-breast irradiation via brachytherapy (APBI-b), but larger, more contemporary studies examining overall APBI use are lacking.

Methods

A total of 575,438 nonneoadjuvant American Joint Committee on Cancer stage 0 to II breast conservation patients were selected from the National Cancer Data Base from 2003 to 2010 who underwent either whole-breast irradiation or APBI.

Results

Overall, 59,396 patients (10.3 %) underwent APBI. The use of APBI for the entire cohort increased from 3.4 % in 2003 to 12.8 % (p < 0.001) in 2008 and then decreased to 12.4 % in 2010. Three-dimensional conformal radiation increased from 0.8 to 2.2 %, intensity-modulated radiotherapy increased from 0.7 to 1.3 %, and brachytherapy (APBI-b) increased from 2.0 to 8.9 %. The most significant factors associated with APBI use were patient age and facility location. Patients 80–89 years old were 3.8 times more likely to undergo APBI compared to patients 30–39 years old (odds ratio [OR] 3.77, 95 % confidence interval [CI] 3.45–4.10, p < 0.001). Patients living in the West census region were 2.0 times more likely to undergo APBI compared to patients living in the Northeast (OR 2.0, 95 % CI 1.93–2.15, p < 0.001). Using the American Society of Radiation Oncology (ASTRO) guidelines, among patients with noninvasive cancer who received APBI, 95.6 % were categorized as “cautionary” and 4.4 % as “unsuitable.” Of the invasive patients, 43.8 % were categorized as “suitable,” 47.0 % as “cautionary,” and 9.2 % as “unsuitable.”

Conclusions

The utilization of APBI has stabilized at approximately 12 % starting in 2008. The majority of APBI is delivered using APBI-b, with patient age being the most significant factor associated with APBI use.
Literatur
1.
Zurück zum Zitat Barry M, Ho A, Morrow M. The evolving role of partial breast irradiation in early-stage breast cancer. Ann Surg Oncol. 2013;20:2534–40.PubMedCrossRef Barry M, Ho A, Morrow M. The evolving role of partial breast irradiation in early-stage breast cancer. Ann Surg Oncol. 2013;20:2534–40.PubMedCrossRef
2.
Zurück zum Zitat Keisch M, Vicini F, Beitch P, et al. American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in situ subset analysis—4 year data in 194 treated lesions. Am J Surg. 2009;198:505–7.PubMedCrossRef Keisch M, Vicini F, Beitch P, et al. American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in situ subset analysis—4 year data in 194 treated lesions. Am J Surg. 2009;198:505–7.PubMedCrossRef
3.
Zurück zum Zitat Giordano S. Radiotherapy in older women with low-risk breast cancer: why did practice not change? J Clin Oncol. 2012;30:1–2.CrossRef Giordano S. Radiotherapy in older women with low-risk breast cancer: why did practice not change? J Clin Oncol. 2012;30:1–2.CrossRef
4.
Zurück zum Zitat Benitez P, Streeter O, Vicini F, et al. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg. 2006;192:427–33.PubMedCrossRef Benitez P, Streeter O, Vicini F, et al. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. Am J Surg. 2006;192:427–33.PubMedCrossRef
5.
Zurück zum Zitat Smith D, Pan IW, Shih YC, et al. Adoption of intensity modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011;103:798–809.PubMedCrossRef Smith D, Pan IW, Shih YC, et al. Adoption of intensity modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst. 2011;103:798–809.PubMedCrossRef
6.
Zurück zum Zitat Smith G, Xu Y, Buchholz TA, et al. Brachytherapy for accelerated partial breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol. 2011;29:157–65.PubMedCrossRef Smith G, Xu Y, Buchholz TA, et al. Brachytherapy for accelerated partial breast irradiation: a rapidly emerging technology in breast cancer care. J Clin Oncol. 2011;29:157–65.PubMedCrossRef
7.
Zurück zum Zitat Zauls A, Watkins JM, Wahlquist AE, et al. Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by accelerated partial breast irradiation consensus statement groups. Int J Radiat Oncol Biol Phys. 2010;8:21–9. Zauls A, Watkins JM, Wahlquist AE, et al. Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by accelerated partial breast irradiation consensus statement groups. Int J Radiat Oncol Biol Phys. 2010;8:21–9.
8.
Zurück zum Zitat Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115–21.PubMedCrossRef Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004;96:115–21.PubMedCrossRef
9.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef
10.
Zurück zum Zitat Fisher B, Jeong JH, Anderson S, et al. Twenty-five year follow up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.PubMedCrossRef Fisher B, Jeong JH, Anderson S, et al. Twenty-five year follow up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567–75.PubMedCrossRef
11.
Zurück zum Zitat Abbott A, Habermann EB, Tuttle TM. Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States. Cancer. 2011;117:3305–10.PubMedCrossRef Abbott A, Habermann EB, Tuttle TM. Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States. Cancer. 2011;117:3305–10.PubMedCrossRef
12.
Zurück zum Zitat Hattangadi J, Taback N, Neville BA, et al. Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst. 2012;104:29–41.PubMedCrossRef Hattangadi J, Taback N, Neville BA, et al. Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst. 2012;104:29–41.PubMedCrossRef
13.
Zurück zum Zitat Bilimoria K, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCrossRef Bilimoria K, Stewart AK, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCrossRef
14.
Zurück zum Zitat Smith B, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society of Radiation Oncology (ASTRO). J Am Coll Surg. 2009;209:269–77.PubMedCrossRef Smith B, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society of Radiation Oncology (ASTRO). J Am Coll Surg. 2009;209:269–77.PubMedCrossRef
15.
Zurück zum Zitat Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Edge S, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
16.
Zurück zum Zitat Fritz A, Jack A, Parkin DM, et al. International classification of diseases for oncology. Geneva: World Health Organization; 2000. Fritz A, Jack A, Parkin DM, et al. International classification of diseases for oncology. Geneva: World Health Organization; 2000.
17.
Zurück zum Zitat United States Census. 2012. Accessed 13 Jan 2013. United States Census. 2012. Accessed 13 Jan 2013.
19.
20.
Zurück zum Zitat Polgar C, Fodor J, Major T, et al. Breast conserving treatment with partial or whole breast irradiation for low risk invasive breast carcinoma—5 year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:509–15.CrossRef Polgar C, Fodor J, Major T, et al. Breast conserving treatment with partial or whole breast irradiation for low risk invasive breast carcinoma—5 year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:509–15.CrossRef
21.
Zurück zum Zitat Polgar C, Strnad V, Kovacs G. Partial-breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized trials. Strahlenther Onkol. 2010;186:113–4.PubMedCrossRef Polgar C, Strnad V, Kovacs G. Partial-breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized trials. Strahlenther Onkol. 2010;186:113–4.PubMedCrossRef
22.
Zurück zum Zitat Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 2010;116:4677–85.PubMedCrossRef Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 2010;116:4677–85.PubMedCrossRef
23.
Zurück zum Zitat Nelson J, Beitsch PD, Vicini FA, et al. Four year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg. 2009;198:83–91.PubMedCrossRef Nelson J, Beitsch PD, Vicini FA, et al. Four year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. Am J Surg. 2009;198:83–91.PubMedCrossRef
24.
Zurück zum Zitat Goyal S, Khan AJ, Vicini F, et al. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MamoXite Breast Brachytherapy registry trial. Ann Surg Oncol. 2009;16:2450–8.PubMedCrossRef Goyal S, Khan AJ, Vicini F, et al. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MamoXite Breast Brachytherapy registry trial. Ann Surg Oncol. 2009;16:2450–8.PubMedCrossRef
25.
Zurück zum Zitat Shah C, McGee M, Wilkinson B, et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer. 2010;12:259–63.CrossRef Shah C, McGee M, Wilkinson B, et al. Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ. Clin Breast Cancer. 2010;12:259–63.CrossRef
26.
Zurück zum Zitat Vicini F, Winter K, Straube W, et al. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) study 0319. Int J Radiat Oncol Biol Phys. 2005;63:1531–7.PubMedCrossRef Vicini F, Winter K, Straube W, et al. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) study 0319. Int J Radiat Oncol Biol Phys. 2005;63:1531–7.PubMedCrossRef
27.
Zurück zum Zitat Vicini F, Winter K, Straube W, et al. Initial efficacy results of RTOG 0319: three dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–7.PubMedCrossRef Vicini F, Winter K, Straube W, et al. Initial efficacy results of RTOG 0319: three dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77:1120–7.PubMedCrossRef
28.
Zurück zum Zitat Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;79:808–17.CrossRef Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;79:808–17.CrossRef
29.
Zurück zum Zitat Smith G, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2010;307:1827–37.CrossRef Smith G, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2010;307:1827–37.CrossRef
30.
Zurück zum Zitat Hughes K, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRef Hughes K, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRef
31.
Zurück zum Zitat Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology, and End Results. J Clin Epidemiol. 1999;52:463–70.PubMedCrossRef Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology, and End Results. J Clin Epidemiol. 1999;52:463–70.PubMedCrossRef
32.
Zurück zum Zitat Malin J, Kahn KL, Adams J, et al. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.PubMedCrossRef Malin J, Kahn KL, Adams J, et al. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.PubMedCrossRef
Metadaten
Titel
Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Early-Stage Breast Cancer Patients Undergoing Breast Conservation, 2003–2010: A Report from the National Cancer Data Base
verfasst von
Tomasz Czechura, MPH
David J. Winchester, MD
Catherine Pesce, MD
Dezheng Huo, MD, PhD
David P. Winchester, MD
Katharine Yao, MD
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3154-8

Weitere Artikel der Ausgabe 10/2013

Annals of Surgical Oncology 10/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.